|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||356.16 - 359.63|
|52 Week Range||302.14 - 359.63|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
With covered calls, you are selling the right for someone else to buy a security from you at a given price on or before a certain date. If you sell covered calls on a stock and that contract gets triggered because the price has gone above that contract’s strike price, you will be forced to sell the stock. The SPDR S&P 500 ETF (NYSEARCA:SPY) is that core ETF that many people own, one which holds all the stocks in the S&P 500.
With just 28 trading days left in 2017, investors have a lot to be thankful for this holiday season. Each news cycle presents an additional challenge for tax reform legislation as it makes its way to the president’s desk. Politics aside, some measure of a tax reform package is priced into the market, and a complete failure would force a reset.
It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.
With large-cap stocks volatile on Trump-Kim Jong-un rift and small-caps having chances of underperformance on some weak U.S. economic data, should you buy mid-cap ETFs?
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.
Investment company Pachira Investments Inc. buys Vanguard Short-Term Bond, sells SPDR MidCap Trust Series I during the 3-months ended 2017-06-30, according to the most recent filings of the investment ...
In 2016, United Therapeutics’ (UTHR) Tyvaso reported revenues of ~$404.0 million, which reflected an ~15.0% decline year-over-year.
In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.
Many ETFs reversed lower along with the broader market, but these two index funds managed to hold gains.
Patterson-UTI Energy's (PTEN) dividend yield fell to 0.29% on March 31, 2017. Since then, its dividend yield has risen to 0.38% as of June 2, 2017.
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
MPC's valuations are above the peer averages likely because it's now in the process of restructuring its organization to unlock value.
In 1Q17, WellCare Health Plans (WCG) reported revenues of ~$3.9 billion, which totals year-over-year growth of around 11.7%.
Since January 3, 2017, TSO stock has fallen 9.8%. Comparatively, crude oil prices have fallen 5.2%, and natural gas prices have fallen 5.6% year-to-date.
Alcoa (AA) released its 1Q17 earnings on April 24 after the markets (MDY) (MID-INDEX) closed. It held the conference call the same day.
Carter Worth, Cornerstone Macro, discusses how to trade technology after the sector dipped. The “Fast Money” traders weigh in.